The University of Chicago Header Logo

Michael Drazer

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Drazer's laboratory research focuses on determining the mechanisms that drive hereditary blood and cancer syndromes, with a particular emphasis on developing "high fidelity" cellular and mouse models of these disorders. He is also involved in the discovery of novel hereditary blood and cancer syndromes. His clinical research is largely focused on optimizing the care of people with hereditary blood and cancer syndromes, including the development of clinical bioinformatics pipelines that improve the diagnosis of patients with these syndromes. He is a member of multiple clinical disease groups at the University of Chicago.

    Collapse Biography 
    Collapse education and training
    Indiana University, BloomingtonBA, BSBiochemistry; Biology; English
    University of Chicago, ChicagoPhDHuman Genetics
    University of Chicago, ChicagoMDMedicine
    University of Chicago, ChicagoResidencyInternal Medicine
    University of Chicago, ChicagoFellowshipHematology/Oncology

    Collapse Featured Content 
    Collapse Featured Videos
    Collapse Twitter

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Roloff GW, Wen F, Ramsland A, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, DuVall AS, Nawas MT, Dworkin E, Wool GD, Gurbuxani S, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239. PMID: 36655425; PMCID: PMC10388285.
      Citations:    Fields:    Translation:Humans
    2. Mitchell OD, Gilliam K, Del Gaudio D, McNeely KE, Smith S, Acevedo M, Gaduraju M, Hodge R, Ramsland ASS, Segal J, Das S, Hathaway F, Bryan DS, Tawde S, Galasinski S, Wang P, Tjota MY, Husain AN, Armato SG, Donington J, Ferguson MK, Turaga K, Churpek JE, Kindler HL, Drazer MW. Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With Mesothelioma. JAMA Netw Open. 2023 08 01; 6(8):e2327351. PMID: 37556141; PMCID: PMC10413174.
      Citations:    Fields:    Translation:Humans
    3. Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez LA, Pozsgai MJ, McNeely KE, Ha TT, Venugopal P, Arts P, King-Smith S, Cheah JJ, Armstrong M, Wang P, Bödör C, Cantor AB, Cazzola M, Degelman ES, DiNardo CD, Duployez N, Favier R, Fröhling S, Rio-Machin A, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Georges N, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff HY, Ripperger T, Schulte RR, Tawana K, Velloso E, Benedict Y, Kim EMK, Sood R, Hsu AP, Holland SM, Phillips K, Poplawski N, Babic M, Wei AH, Forsyth CJ, Mar Fan H, Lewis I, Cooney JP, Susman R, Fox LC, Blombery P, Singhal D, Hiwase DK, Phipson B, Schreiber AW, Hahn CN, Scott HS, Liu PP, Godley LA, Brown AL. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants. Blood Adv. 2023 Jul 05. PMID: 37406166.
      Citations:    Fields:    
    4. Hamidi A, Roloff GW, Shaw R, Acevedo M, Smith S, Drazer MW. Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes. Leuk Lymphoma. 2023 Sep; 64(9):1562-1565. PMID: 37294121.
      Citations:    Fields:    Translation:Humans
    5. Berger Y, Gadiraju M, Dhiman A, Gilliam K, Opalecky B, Chen H, Helgeson M, Eng OS, Husain AN, Drazer MW, Kindler HL, Churpek JE, Turaga KK. Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. Cancer. 2023 07 15; 129(14):2152-2160. PMID: 37042570.
      Citations:    Fields:    Translation:Humans
    6. Roloff GW, Shaw R, O'Connor TE, Hathaway F, Drazer MW. Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies. J Genet Couns. 2023 06; 32(3):744-749. PMID: 36642751.
      Citations: 1     Fields:    Translation:Humans
    7. Feurstein S, Trottier AM, Estrada-Merly N, Pozsgai M, McNeely K, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu Z, Sobecks R, Spellman S, Saber W, Godley LA. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022 12 15; 140(24):2533-2548. PMID: 35969835; PMCID: PMC9918848.
      Citations: 6     Fields:    Translation:HumansCells
    8. Homan CC, Yu K, Segal JP, Wang P, Feng J, King-Smith SL, Kim E, Lawrence DM, Schreiber AW, Hahn CN, Scott HS, Sood R, NISC Comparative Sequencing Program, Velloso EDRP, Brown AL, Liu PP, Drazer MW, Cavalcante de Andrade Silva M, McNeely KE, Pozsgai MJ, Acevedo-Mendez MG, Korotev S, Godley LA. Clonal hematopoiesis in patients with ANKRD26 or ETV6 germline mutations. Blood Adv. 2022 08 09; 6(15):4357-4359. PMID: 35537115; PMCID: PMC9636309.
      Citations: 1     Fields:    Translation:Humans
    9. Wang P, Segal J, Drazer MW, Venkataraman G, Arber DA, Gurbuxani S. NPM1 exon 5 mutations in acute myeloid leukemia: Implications in diagnosis and minimal residual monitoring. EJHaem. 2022 Aug; 3(3):962-965. PMID: 36051025; PMCID: PMC9421992.
    10. Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Cantor A, Cazzola M, Degelman E, DiNardo CD, Duployez N, Fitzgibbon J, Klco JM, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown AL, Bödör C, Favier R, Fröhling S, Krämer A, Raslova H. The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 11 01; 106(11):3004-3007. PMID: 34233450; PMCID: PMC8561292.
      Citations: 9     Fields:    Translation:Humans
    11. Roloff GW, Drazer MW, Godley LA. Inherited Susceptibility to Hematopoietic Malignancies in the Era of Precision Oncology. JCO Precis Oncol. 2021 11; 5:107-122. PMID: 34994594.
      Citations: 7     Fields:    Translation:Humans
    12. Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM, Larson RA. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148. PMID: 34492705; PMCID: PMC8945635.
      Citations: 4     Fields:    Translation:HumansCells
    13. Feurstein S, Drazer M, Godley LA. Germline predisposition to hematopoietic malignancies. Hum Mol Genet. 2021 10 01; 30(20):R225-R235. PMID: 34100074.
      Citations: 10     Fields:    Translation:Humans
    14. White MG, Morgan RB, Drazer MW, Eng OS. Gastrointestinal Surgical Emergencies in the Neutropenic Immunocompromised Patient. J Gastrointest Surg. 2021 12; 25(12):3258-3264. PMID: 34506017; PMCID: PMC8665083.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    15. Borst S, Nations CC, Klein JG, Pavani G, Maguire JA, Camire RM, Drazer MW, Godley LA, French DL, Poncz M, Gadue P. Study of inherited thrombocytopenia resulting from mutations in ETV6 or RUNX1 using a human pluripotent stem cell model. Stem Cell Reports. 2021 06 08; 16(6):1458-1467. PMID: 34019812; PMCID: PMC8190596.
      Citations: 5     Fields:    Translation:HumansCells
    16. Roloff GW, Godley LA, Drazer MW. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genet Med. 2021 01; 23(1):211-214. PMID: 32807974; PMCID: PMC9299956.
      Citations: 4     Fields:    Translation:HumansCells
    17. Akpan IJ, Osman AEG, Drazer MW, Godley LA. Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. Curr Hematol Malig Rep. 2018 12; 13(6):426-434. PMID: 30259338.
      Citations: 4     Fields:    Translation:Humans
    18. Walsh MF, Ritter DI, Kesserwan C, Sonkin D, Chakravarty D, Chao E, Ghosh R, Kemel Y, Wu G, Lee K, Kulkarni S, Hedges D, Mandelker D, Ceyhan-Birsoy O, Luo M, Drazer M, Zhang L, Offit K, Plon SE. Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. Hum Mutat. 2018 11; 39(11):1542-1552. PMID: 30311369; PMCID: PMC6310222.
      Citations: 17     Fields:    Translation:Humans
    19. Drazer MW, Sweis RF. Low clinical adoption of tumor genomic profiling: cause for concern? J Med Econ. 2018 Jul; 21(7):721-723. PMID: 29708449; PMCID: PMC6062854.
      Citations:    Fields:    Translation:Humans
    20. Tawana K, Drazer MW, Churpek JE. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet? Leukemia. 2018 07; 32(7):1482-1492. PMID: 29483711.
      Citations: 22     Fields:    Translation:Humans
    21. Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty CK, Raca G, Lingen MW, Li Z, Segal JP, Churpek JE, Godley LA, Ceballos-López AA. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018 01 23; 2(2):146-150. PMID: 29365323; PMCID: PMC5787862.
      Citations: 32     Fields:    Translation:HumansCells
    22. Drazer MW, Godley LA, Feurstein S. Genetic predisposition to leukemia and other hematologic malignancies. Semin Oncol. 2016 Oct; 43(5):598-608. PMID: 27899193.
      Citations: 29     Fields:    Translation:Humans
    23. Drazer MW, Stadler WM. The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. Cancer J. 2016 Sep/Oct; 22(5):330-333. PMID: 27749326; PMCID: PMC5108565.
      Citations: 5     Fields:    Translation:Humans
    24. Drazer MW, Eggener SE. Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Ann Intern Med. 2016 05 17; 164(10):702-3. PMID: 27182910.
      Citations:    Fields:    Translation:HumansPHPublic Health
    25. Drazer MW, Salama JK, Hahn OM, Weichselbaum RR, Chmura SJ. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32. PMID: 27078719.
      Citations: 1     Fields:    Translation:Humans
    26. Sweis RF, Drazer MW, Ratain MJ. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74. PMID: 26668350; PMCID: PMC4872035.
      Citations: 12     Fields:    Translation:Humans
    27. Drazer MW, Huo D, Eggener SE. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23. PMID: 26056181.
      Citations: 74     Fields:    Translation:HumansPHPublic Health
    28. Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8. PMID: 24523016.
      Citations: 34     Fields:    Translation:HumansPHPublic Health
    29. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4. PMID: 22535850.
      Citations: 17     Fields:    Translation:HumansPHPublic Health
    30. Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011 Aug; 60(2):374-9. PMID: 21612857.
      Citations: 45     Fields:    Translation:Humans
    31. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43. PMID: 21444863; PMCID: PMC4821471.
      Citations: 48     Fields:    Translation:HumansPHPublic Health
    32. Ybe JA, Perez-Miller S, Niu Q, Coates DA, Drazer MW, Clegg ME. Light chain C-terminal region reinforces the stability of clathrin heavy chain trimers. Traffic. 2007 Aug; 8(8):1101-10. PMID: 17555534.
      Citations: 17     Fields:    Translation:AnimalsCells
    Drazer's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (133)
    Co-Authors (35)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors